BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33838155)

  • 1. MiR-3663-3p participates in the anti-hepatocellular carcinoma proliferation activity of baicalein by targeting SH3GL1 and negatively regulating EGFR/ERK/NF-κB signaling.
    Tian J; Li J; Bie B; Sun J; Mu Y; Shi M; Zhang S; Kong G; Li Z; Guo Y
    Toxicol Appl Pharmacol; 2021 Jun; 420():115522. PubMed ID: 33838155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-342-3p affects hepatocellular carcinoma cell proliferation via regulating NF-κB pathway.
    Zhao L; Zhang Y
    Biochem Biophys Res Commun; 2015 Feb; 457(3):370-7. PubMed ID: 25580008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-6809-5p mediates luteolin-induced anticancer effects against hepatoma by targeting flotillin 1.
    Yang PW; Lu ZY; Pan Q; Chen TT; Feng XJ; Wang SM; Pan YC; Zhu MH; Zhang SH
    Phytomedicine; 2019 Apr; 57():18-29. PubMed ID: 30668319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mir-452-3p: A Potential Tumor Promoter That Targets the CPEB3/EGFR Axis in Human Hepatocellular Carcinoma.
    Tang H; Zhang J; Yu Z; Ye L; Li K; Ding F; Feng X; Meng W
    Technol Cancer Res Treat; 2017 Dec; 16(6):1136-1149. PubMed ID: 29332449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midazolam inhibits proliferation and accelerates apoptosis of hepatocellular carcinoma cells by elevating microRNA-124-3p and suppressing PIM-1.
    Qi Y; Yao X; Du X
    IUBMB Life; 2020 Mar; 72(3):452-464. PubMed ID: 31651086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-128-3p overexpression sensitizes hepatocellular carcinoma cells to sorafenib induced apoptosis through regulating DJ-1.
    Guo XL; Wang HB; Yong JK; Zhong J; Li QH
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6667-6677. PubMed ID: 30402839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosomal lncRNA H19 promotes the progression of hepatocellular carcinoma treated with Propofol via miR-520a-3p/LIMK1 axis.
    Wang D; Xing N; Yang T; Liu J; Zhao H; He J; Ai Y; Yang J
    Cancer Med; 2020 Oct; 9(19):7218-7230. PubMed ID: 32767662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma.
    Zhang Y; Xu J; Zhang S; An J; Zhang J; Huang J; Jin Y
    Cell Physiol Biochem; 2018; 50(6):2124-2138. PubMed ID: 30415263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway.
    Li T; Dong ZR; Guo ZY; Wang CH; Zhi XT; Zhou JW; Li DK; Chen ZT; Chen ZQ; Hu SY
    Liver Int; 2015 Apr; 35(4):1416-29. PubMed ID: 25066210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-27a-3p enhances the cisplatin sensitivity in hepatocellular carcinoma cells through inhibiting PI3K/Akt pathway.
    Yang Y; Yang Z; Zhang R; Jia C; Mao R; Mahati S; Zhang Y; Wu G; Sun YN; Jia XY; Aimudula A; Zhang H; Bao Y
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34096570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
    PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-449a suppresses hepatocellular carcinoma cell growth via G1 phase arrest and the HGF/MET c-Met pathway.
    Cheng J; Wu LM; Deng XS; Wu J; Lv Z; Zhao HF; Yang Z; Ni Y
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):336-344. PubMed ID: 30108016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5.
    Cao Y; Chen J; Wang D; Peng H; Tan X; Xiong D; Huang A; Tang H
    Oncotarget; 2015 Nov; 6(35):38093-106. PubMed ID: 26497554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells.
    Liao YJ; Bai HY; Li ZH; Zou J; Chen JW; Zheng F; Zhang JX; Mai SJ; Zeng MS; Sun HD; Pu JX; Xie D
    Cell Death Dis; 2014 Mar; 5(3):e1137. PubMed ID: 24651440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catalpol inhibits cell proliferation, invasion and migration through regulating miR-22-3p/MTA3 signalling in hepatocellular carcinoma.
    Zhao L; Wang Y; Liu Q
    Exp Mol Pathol; 2019 Aug; 109():51-60. PubMed ID: 31145886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long noncoding RNA NKILA enhances the anti-cancer effects of baicalein in hepatocellular carcinoma via the regulation of NF-κB signaling.
    Yu X; Tang W; Yang Y; Tang L; Dai R; Pu B; Feng C; Xia J
    Chem Biol Interact; 2018 Apr; 285():48-58. PubMed ID: 29481769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrine derivative WM130 inhibits hepatocellular carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways.
    Qian L; Liu Y; Xu Y; Ji W; Wu Q; Liu Y; Gao Q; Su C
    Cancer Lett; 2015 Nov; 368(1):126-134. PubMed ID: 26259512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3.
    Zhao N; Wang R; Zhou L; Zhu Y; Gong J; Zhuang SM
    Mol Cancer; 2014 Feb; 13():35. PubMed ID: 24565101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-6875-3p promotes the proliferation, invasion and metastasis of hepatocellular carcinoma via BTG2/FAK/Akt pathway.
    Xie Y; Du J; Liu Z; Zhang D; Yao X; Yang Y
    J Exp Clin Cancer Res; 2019 Jan; 38(1):7. PubMed ID: 30621734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.